Eagle Pharmaceuticals Inc

NASDAQ:EGRX   10:10:01 AM EDT
47.59
+0.17 (+0.36%)
Earnings Announcements

Eagle Pharmaceuticals Reports Third Quarter 2021 Results

Published: 11/09/2021 11:58 GMT
Eagle Pharmaceuticals Inc (EGRX) - Eagle Pharmaceuticals Reports Third Quarter 2021 Results.
Q3 Adjusted Non-GAAP Earnings per Share $0.56.
Q3 Loss per Share $0.43.
Q3 Revenue $39.9 Million.
Expect to Receive Approval for Abbreviated New Drug Application ("anda") for Vasopressin; December 15, 2021 Gdufa Date.
Revenue is expected to be $51.54 Million
Adjusted EPS is expected to be $0.95

Next Quarter Revenue Guidance is expected to be $62.7 Million
Next Quarter EPS Guidance is expected to be $1.12

More details on our Analysts Page.